News &amp; Updates

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) results in a decrease in deaths and major adverse cardiovascular events (MACE) in high-risk patients, reports as study.

GLP-1 RAs reduce deaths, MACE in at-risk individuals

Behavioural problems prevalent in kids with adverse childhood experiences

Exposure to adverse childhood experiences (ACEs) appears to result in developmental, academic, and behavioural concerns among kindergarten children, suggests a Singapore study.

Behavioural problems prevalent in kids with adverse childhood experiences

Repeat POEM works well against persistent achalasia symptoms

Patients with persistent symptoms of achalasia may benefit from repeat per-oral endoscopic myotomy (POEM) following a failed initial procedure, suggests a study.

Repeat POEM works well against persistent achalasia symptoms

Sparsentan remains superior to irbesartan for IgAN in post hoc analysis

In the post hoc analysis of the phase III PROTECT trial, the non-immunosuppressive dual endothelin angiotensin receptor antagonist sparsentan remains superior to irbesartan for the treatment of immunoglobulin A nephropathy (IgAN).

Sparsentan remains superior to irbesartan for IgAN in post hoc analysis

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

Discontinuing treatment with GLP-1RAs before or early into pregnancy in women with obesity may lead to more gestational weight gain and increased risk of preterm delivery, gestational diabetes, and hypertensive disorders of pregnancy, according to a retrospective study.

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

Mortality in first-time psychosis: 25-year study sheds light on trajectories & at-risk groups

In patients with first-episode psychosis, the cumulative incidence of unnatural deaths (mostly suicide) rises sharply during the first 10 years, while deaths from natural causes begin to increase after the first decade, a 25-year population-based cohort study in Hong Kong has shown.

Mortality in first-time psychosis: 25-year study sheds light on trajectories & at-risk groups

ICI-induced endocrinopathies: Patient education, regular monitoring, and early appropriate management important

Regular monitoring and recognizing tell-tale signs upon first presentation are important in managing endocrine immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs), for optimized cancer treatment outcomes, stressed Dr David Lui from the University of Hong Kong, at the 8^th Endocrinology, Diabetes & Metabolism Hong Kong Annual Meeting (EDM HK 2025).

ICI-induced endocrinopathies: Patient education, regular monitoring, and early appropriate management important

Fixed-dose balcinrenone–dapagliflozin combo works in high-risk CKD

In the treatment of patients with chronic kidney disease (CKD) at high risk of progression, a fixed dose combination of balcinrenone and dapagliflozin is well tolerated and results in greater reductions in albuminuria as compared with dapagliflozin alone in reducing albuminuria, according to the phase IIb MIRO-CKD study.

Fixed-dose balcinrenone–dapagliflozin combo works in high-risk CKD

Evolocumab slashes risk of first cardiac events in patients without prior MI or stroke

27 Nov 2025 by

The PCSK9 inhibitor evolocumab, when added to background lipid-lowering therapy, helps reduce the risk of major adverse cardiovascular events in patients with atherosclerosis or diabetes who have no history of myocardial infarction (MI) or stroke, according to the randomized VESALIUS-CV trial.

Evolocumab slashes risk of first cardiac events in patients without prior MI or stroke

Endoscopic submucosal dissection safe, effective for RNDLs

A recent study has shown the safety and efficacy of endoscopic submucosal dissection (ESD) in the management of rectal neoplasms extending to the dentate line (RNDLs), which also boasts of a low recurrence rate.

Endoscopic submucosal dissection safe, effective for RNDLs